Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits

被引:13
|
作者
Candas, B
Labrie, F
Gomez, JL
Cusan, L
Chevrette, E
Lévesque, J
Brousseau, G
机构
[1] Laval Univ Hosp, Mol Endocrinol & Oncol Res Ctr, Res Ctr, Ctr Hosp, Quebec City, PQ G1V 4G2, Canada
[2] Laval Univ Hosp, Dept Med, Res Ctr, Quebec City, PQ, Canada
[3] Laval Univ Hosp, Ctr Hosp, Prostate Canc Clin, Quebec City, PQ, Canada
[4] Univ Laval, Dept Physiol & Anat, Quebec City, PQ G1K 7P4, Canada
[5] Laval Univ Hosp, Dept Radiol, Res Ctr, Laval, PQ, Canada
来源
JOURNAL OF UROLOGY | 2006年 / 175卷 / 02期
关键词
prostate; prostatic neoplasms; mass screening; prostate-specific antigen;
D O I
10.1016/S0022-5347(05)00165-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the probability of positive serum PSA (3 ng/ml or greater) and CaP detection at annual followup visits in men with negative initial PSA (less than 3 ng/ml) to optimize the re-screening schedule. Materials and Methods: Data on 5,387 men 45 to 80 years old with negative PSA and no CaP diagnosis at the first screening visit were obtained from the Laval University Prostate Cancer Screening Program database. Accelerated failure time regressions were fitted to time from baseline to positive PSA and to time from positive PSA to CaP detection. The models were combined to estimate the cumulative probability of positive PSA followed by CaP detection at re-screening. Results: The 5-year cumulative probability of detecting CaP at annual visits in men with baseline PSA up to 1.5 ng/ml remained below 0.8%, while it was 1.3%, 4.8% and 8.3% in men with PSA 1.5 to less than 2, 2 to less than 2.5 and 2.5 to less than 3 ng/ml, respectively. Time to positive PSA significantly decreased with increasing baseline PSA and age, while the time between positive PSA and CaP detection depended only on age. Men with PSA below 1.0 ng/ml could wait for 4 to 5 years before being re-tested, while men with PSA between 1.0 and 1.5 ng/ml should be screened every second year and men with PSA 1.5 ng/ml or greater should be screened every year. Conclusions: The proposed retesting schedule using current PSA and age decreases the number of visits by 38.1%, while delaying the detection of only 2.4% of CaPs that would have been detected using annual PSA testing.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 50 条
  • [11] SERUM PROSTATE-SPECIFIC ANTIGEN AND THE BIOLOGIC PROGRESSION OF PROSTATE-CANCER
    KABALIN, JN
    MCNEAL, JE
    JOHNSTONE, IM
    STAMEY, TA
    UROLOGY, 1995, 46 (01) : 65 - 70
  • [12] Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection
    Freedland, SJ
    Platz, EA
    Presti, JC
    Aronson, WJ
    Amling, CL
    Kane, CJ
    Terris, MK
    JOURNAL OF UROLOGY, 2006, 175 (02): : 500 - 504
  • [13] Free serum prostate-specific antigen and screening for prostate cancer - Reply
    Catalona, WJ
    Smith, DS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (11): : 838 - 838
  • [14] BIOMARKERS FOR PROSTATE CANCER DETECTION AND, PROGRESSION: BEYOND PROSTATE-SPECIFIC ANTIGEN
    Berney, Daniel M.
    DRUG NEWS & PERSPECTIVES, 2010, 23 (03) : 185 - 194
  • [15] Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening
    Moul, Judd W.
    Sun, Leon
    Hotaling, James M.
    Fitzsimons, Nicholas J.
    Polascik, Thomas J.
    Robertson, Cary N.
    Dahm, Philipp
    Anscher, Mitchell S.
    Mouraviev, Vladimir
    Pappas, Paul A.
    Albala, David M.
    JOURNAL OF UROLOGY, 2007, 177 (02): : 499 - 503
  • [16] Prostate cancer detection at low prostate specific antigen
    Schröder, FH
    van der Cruijsen-Koeter, I
    de Koning, HJ
    Vis, AN
    Hoedemaeker, RF
    Kranse, R
    JOURNAL OF UROLOGY, 2000, 163 (03): : 806 - 811
  • [17] Detection of prostate cancer by prostate-specific antigen
    Egawa, S
    BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (03) : 130 - 134
  • [18] Prostate specific antigen changes as related to initial prostate specific antigen: Data from prostate, lung, colorectal and ovarian cancer screening trial
    Crawford, ED
    Pinsky, PF
    Chia, D
    Kramer, BS
    Fagerstrom, RM
    Andriole, G
    Reding, D
    Gelmann, EP
    Levin, DL
    Gohagan, JK
    JOURNAL OF UROLOGY, 2006, 175 (04): : 1286 - 1290
  • [19] Mass screening of prostate cancer in a Chinese population:the relationship between pathological features of prostate cancer and serum prostate specific antigen
    Hiroo Tateno
    Ikuro Sato
    Masaaki Kuwahara
    AsianJournalofAndrology, 2005, (02) : 159 - 163
  • [20] Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen
    Gao, HW
    Li, YL
    Wu, S
    Wang, YS
    Zhang, HF
    Pan, YZ
    Zhang, L
    Tateno, H
    Sato, I
    Kuwahara, M
    Zhao, XJ
    ASIAN JOURNAL OF ANDROLOGY, 2005, 7 (02) : 159 - 163